Advocacy intelligence hub — real-time data for patient organizations
Yervoy: FDA approved
For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Browse all Rare parathyroid disease and phosphocalcic metabolism anomaly news →
View all Rare parathyroid disease and phosphocalcic metabolism anomaly specialists →